HighVista Strategies LLC - ALPINE IMMUNE SCIENCES INC ownership

Quarter-by-quarter ownership
HighVista Strategies LLC ownership history of ALPINE IMMUNE SCIENCES INC
ValueSharesWeighting
Q3 2023$456,408
-50.8%
39,861
-55.9%
0.21%
-50.4%
Q2 2023$928,150
+33.2%
90,2870.0%0.42%
-25.2%
Q1 2023$697,016
+358.6%
90,287
+532.8%
0.57%
+462.4%
Q3 2021$152,00014,2680.10%
Other shareholders
ALPINE IMMUNE SCIENCES INC shareholders Q4 2023
NameSharesValueWeighting ↓
Decheng Capital Management III (Cayman), LLC 4,708,288$42,233,00012.94%
Lynx1 Capital Management LP 1,484,693$13,318,00012.36%
Omega Fund Management, LLC 2,029,580$18,205,0003.73%
TCG Crossover Management, LLC 1,034,222$9,277,0003.72%
Frazier Life Sciences Management, L.P. 4,185,757$37,546,0003.20%
Paradigm Biocapital Advisors LP 336,229$3,016,0000.80%
Orbimed Advisors 4,081,592$36,612,0000.59%
BVF INC/IL 1,589,495$14,258,0000.57%
Kingsbury Capital Investment Advisors LLC 29,153$262,0000.29%
Avidity Partners Management LP 1,207,000$10,827,0000.22%
View complete list of ALPINE IMMUNE SCIENCES INC shareholders